Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 15733382 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | February 2021 | August 2024 | Abandon | 49 | 0 | 1 | No | No |
| 17136276 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | December 2020 | December 2021 | Allow | 12 | 0 | 0 | No | No |
| 17133362 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | December 2020 | January 2023 | Allow | 25 | 1 | 0 | No | No |
| 17255632 | 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS | December 2020 | June 2022 | Abandon | 18 | 1 | 0 | No | No |
| 17255750 | NEW CRBN MODULATORS | December 2020 | February 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17128584 | METHODS FOR TREATMENT OF HEART FAILURE | December 2020 | July 2022 | Abandon | 19 | 1 | 0 | No | No |
| 17254565 | NADPH OXIDASE INHIBITORS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND APPLICATION THEREOF | December 2020 | January 2023 | Allow | 25 | 3 | 1 | Yes | No |
| 17126152 | PROCESS FOR PREPARING ISOCYANURATE | December 2020 | April 2022 | Allow | 16 | 1 | 0 | No | No |
| 17252841 | CYSTEINE-DEPENDENT INVERSE AGONISTS OF NUCLEAR RECEPTORS ROR-GAMMA/ROR-GAMMA-T AND METHODS OF TREATING DISEASES OR DISORDERS THEREWITH | December 2020 | March 2024 | Allow | 39 | 2 | 1 | No | No |
| 16962394 | METHOD FOR PREPARING N-ALKOXYCARBONYLPIPERIDINE DERIVATIVE, AND INTERMEDIATE THEREFOR | December 2020 | March 2022 | Allow | 20 | 1 | 0 | No | No |
| 17251295 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | December 2020 | August 2023 | Allow | 32 | 2 | 1 | Yes | No |
| 16973941 | Glucose Uptake Inhibitors | December 2020 | February 2024 | Allow | 39 | 4 | 1 | No | No |
| 16973443 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | December 2020 | March 2023 | Allow | 27 | 4 | 1 | No | No |
| 15734293 | Triazine Compounds and Uses Thereof | December 2020 | October 2022 | Abandon | 22 | 0 | 1 | No | No |
| 17108199 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | December 2020 | March 2022 | Allow | 15 | 0 | 0 | No | No |
| 17058979 | TLR7 AGONIST AND PHARMACEUTICAL COMBINATION THEREOF FOR TREATING LUNG CANCER | November 2020 | June 2024 | Allow | 43 | 1 | 1 | No | No |
| 17102672 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | November 2020 | December 2023 | Allow | 37 | 4 | 1 | Yes | No |
| 17095672 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | November 2020 | February 2022 | Allow | 15 | 1 | 0 | No | No |
| 17052626 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AS LSD-1 INHIBITORS | November 2020 | November 2023 | Allow | 37 | 1 | 0 | No | No |
| 17052791 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | November 2020 | November 2023 | Allow | 36 | 1 | 0 | No | No |
| 17052595 | INHIBITORS OF RSV REPLICATION AND APPLICATIONS THEREOF | November 2020 | February 2024 | Allow | 40 | 1 | 1 | No | No |
| 17087483 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | November 2020 | May 2022 | Allow | 18 | 1 | 0 | No | No |
| 17050744 | AQUEOUS DISPERSION OF A POLYURETHANE COMPRISING A DICARBOXYLATE WITH ONE OR TWO SECONDARY AMINO GROUP | October 2020 | June 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17076356 | SYNTHESIS OF CERDULATINIB | October 2020 | January 2022 | Allow | 15 | 1 | 0 | No | No |
| 17074337 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | October 2020 | March 2021 | Allow | 5 | 1 | 0 | Yes | No |
| 17073620 | METHODS OF INHIBITING MMP-9 | October 2020 | April 2021 | Allow | 6 | 0 | 0 | Yes | No |
| 17032486 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | September 2020 | May 2022 | Abandon | 19 | 1 | 0 | No | No |
| 17030073 | DITHIO ETP DERIVATIVES | September 2020 | October 2022 | Allow | 25 | 2 | 0 | No | No |
| 17030268 | NOVEL COMPOUNDS | September 2020 | August 2022 | Allow | 23 | 2 | 0 | No | No |
| 17040894 | PREPARATION METHOD FOR AZOXYSTROBIN AND INTERMEDIATE THEREOF | September 2020 | October 2021 | Allow | 13 | 1 | 0 | No | No |
| 17027637 | THERAPEUTIC INHIBITORY COMPOUNDS | September 2020 | May 2022 | Abandon | 19 | 1 | 0 | No | No |
| 16982745 | AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE | September 2020 | March 2022 | Allow | 18 | 1 | 1 | No | No |
| 17025790 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | September 2020 | July 2022 | Allow | 22 | 0 | 1 | No | No |
| 16982354 | ARYLNAPHTHALENE COMPOUNDS AS VACUOLAR-ATPASE INHIBITORS AND THE USE THEREOF | September 2020 | October 2022 | Allow | 25 | 3 | 0 | No | No |
| 17015450 | PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR, AND PRECURSORS THEREOF | September 2020 | July 2022 | Allow | 22 | 1 | 1 | No | No |
| 17014011 | THERAPEUTIC AGENT FOR LUNG CANCER THAT HAS ACQUIRED EGFR-TKI RESISTANCE | September 2020 | April 2022 | Allow | 19 | 1 | 0 | No | No |
| 16977251 | NOVEL COMPOUNDS | September 2020 | March 2023 | Allow | 31 | 2 | 1 | No | No |
| 17004943 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | August 2020 | November 2021 | Allow | 15 | 1 | 0 | Yes | No |
| 16976382 | TWO-PART NITRIC OXIDE GENERATING TOPICAL COMPOSITIONS | August 2020 | January 2024 | Allow | 41 | 1 | 0 | No | No |
| 16975784 | 10-(DI(PHENYL)METHYL)-4-HYDROXY-8,9,9A,10-TETRAHYDRO-7H-PYRROLO[1 ',2':4,5]PYRAZINO[1,2-B]PYRIDAZINE-3,5-DIONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE ORTHOMYXOVIRUS REPLICATION FOR TREATING INFLUENZA | August 2020 | August 2022 | Allow | 23 | 1 | 1 | No | No |
| 16999295 | SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS | August 2020 | December 2020 | Allow | 4 | 1 | 0 | No | No |
| 16970931 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | August 2020 | October 2022 | Allow | 26 | 2 | 1 | No | No |
| 16947650 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | August 2020 | January 2021 | Allow | 5 | 1 | 0 | No | No |
| 16947651 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | August 2020 | May 2021 | Allow | 9 | 1 | 1 | No | No |
| 16990677 | PYRIDAZINONES AS PARP7 INHIBITORS | August 2020 | January 2021 | Allow | 5 | 1 | 0 | No | No |
| 16988775 | Process for Preparing a Triazine-Based Precursor, the Precursor Prepared Thereby, a Method for Producing a Micro-Particulate Complex Using the Precursor, and the Micro-Particulate Complex Produced Thereby | August 2020 | January 2022 | Allow | 17 | 1 | 0 | No | No |
| 16968273 | HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE | August 2020 | February 2023 | Abandon | 30 | 2 | 1 | No | No |
| 16983768 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | August 2020 | December 2021 | Allow | 17 | 1 | 0 | No | No |
| 16940542 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | July 2020 | October 2022 | Abandon | 27 | 2 | 0 | No | No |
| 16937855 | NITROGEN-CONTAINING HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY | July 2020 | January 2021 | Allow | 6 | 1 | 0 | No | No |
| 16937877 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | July 2020 | December 2021 | Allow | 17 | 1 | 0 | No | No |
| 16964228 | Compounds for the Treatment of Kinase-Dependent Disorders | July 2020 | March 2023 | Allow | 32 | 3 | 1 | No | No |
| 16963810 | PYRIDAZINONE-SUBSTITUTED KETOXIMES AS HERBICIDES | July 2020 | January 2022 | Abandon | 18 | 1 | 0 | No | No |
| 16926059 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | July 2020 | December 2022 | Abandon | 29 | 2 | 0 | No | No |
| 16961362 | CRBN LIGANDS AND USES THEREOF | July 2020 | July 2022 | Allow | 24 | 1 | 1 | No | No |
| 16960912 | INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 (BCL9) PROTEIN-PROTEIN INTERACTION | July 2020 | August 2022 | Abandon | 26 | 1 | 1 | No | No |
| 16960470 | FUROXAN-BASED COMPOUNDS AND USES THEREOF | July 2020 | July 2022 | Allow | 24 | 2 | 1 | Yes | No |
| 16920220 | DIAGNOSIS AND REGULATION OF EPIDERMAL DIFFERENTIATION AND CANCER CELL ACTIVITY | July 2020 | January 2023 | Allow | 31 | 1 | 0 | No | No |
| 16912965 | CRYSTALLINE FORM OF N-[5-(3,5-DIFLUORO-BENZYL)-1H-INDAZOL-3-YL]-4-(4-METHYL-PIPERAZIN-1-YL)-2-(TETRAHYDRO-PYRAN-4-YLAMINO)-BENZAMIDE | June 2020 | March 2021 | Allow | 8 | 2 | 0 | No | No |
| 16910208 | ERBB/BTK INHIBITORS | June 2020 | January 2021 | Allow | 6 | 1 | 0 | No | No |
| 16910688 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | June 2020 | March 2022 | Allow | 20 | 1 | 1 | No | No |
| 16909862 | 6-AMINOURACIL CASSIC ACID ESTER WITH ANTIBACTERIAL ACTIVITY AND A METHOD OF PREPARING THE SAME | June 2020 | January 2021 | Allow | 7 | 0 | 0 | No | No |
| 16902935 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | June 2020 | June 2021 | Allow | 12 | 0 | 0 | No | No |
| 16954514 | Compounds and Compositions for Treating Fibrosis | June 2020 | July 2022 | Allow | 25 | 2 | 1 | No | No |
| 16901601 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | June 2020 | August 2022 | Allow | 26 | 0 | 0 | No | No |
| 16772825 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | June 2020 | October 2021 | Allow | 16 | 1 | 0 | No | No |
| 16893981 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | June 2020 | August 2022 | Allow | 26 | 2 | 0 | No | No |
| 16883046 | AUTOPHAGY MODULATORS FOR USE IN TREATING CANCER | May 2020 | June 2022 | Allow | 25 | 1 | 0 | No | No |
| 16766258 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | May 2020 | February 2022 | Allow | 21 | 2 | 0 | No | No |
| 16874961 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | May 2020 | September 2020 | Allow | 4 | 1 | 0 | No | No |
| 16875917 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | May 2020 | July 2022 | Allow | 26 | 2 | 1 | No | No |
| 15930309 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | May 2020 | August 2020 | Allow | 3 | 2 | 0 | No | No |
| 16871143 | ISOTOPOLOGUES OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE | May 2020 | December 2020 | Allow | 7 | 1 | 0 | No | No |
| 16870249 | Microbiocidal Oxadiazole Derivatives | May 2020 | November 2020 | Allow | 7 | 2 | 0 | No | No |
| 16759782 | MULTICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | April 2020 | March 2022 | Allow | 22 | 1 | 0 | No | No |
| 16757008 | SYNTHESIS OF 4-AMINOPYRIMIDINE COMPOUNDS | April 2020 | August 2021 | Allow | 16 | 1 | 0 | No | No |
| 16757072 | INHIBITORS OF MUTANT FAMILY TYROSINE-KINASES | April 2020 | July 2022 | Allow | 27 | 2 | 1 | No | No |
| 16850171 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | April 2020 | July 2022 | Allow | 26 | 2 | 1 | No | No |
| 16847477 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | April 2020 | June 2020 | Allow | 2 | 0 | 0 | No | No |
| 16844262 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | April 2020 | July 2022 | Abandon | 27 | 2 | 0 | No | No |
| 16754171 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | April 2020 | January 2023 | Allow | 33 | 2 | 1 | No | No |
| 16754044 | PROCESS FOR PREPARING SPIRO DERIVATIVES | April 2020 | June 2021 | Allow | 14 | 1 | 0 | No | No |
| 16651256 | COMPOSITIONS AND METHODS FOR TREATING CANCER | March 2020 | October 2023 | Abandon | 43 | 2 | 1 | No | No |
| 16826623 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | March 2020 | January 2022 | Allow | 22 | 3 | 0 | Yes | No |
| 16825324 | CYTOSINE-BASED TET ENZYME INHIBITORS | March 2020 | July 2022 | Allow | 28 | 2 | 0 | No | No |
| 16648263 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | March 2020 | February 2022 | Allow | 23 | 1 | 0 | No | No |
| 16616340 | PYRAN FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | March 2020 | March 2022 | Allow | 28 | 1 | 0 | No | No |
| 16644919 | AROMATIC DERIVATIVE, PREPARATION METHOD FOR SAME, AND MEDICAL APPLICATIONS THEREOF | March 2020 | November 2021 | Allow | 20 | 1 | 0 | Yes | No |
| 16642824 | FUSED RING COMPOUNDS | February 2020 | March 2023 | Allow | 37 | 3 | 1 | Yes | No |
| 16641450 | A MULTIVALENT LIGAND FOR MYOTONIC DYSTROPHY | February 2020 | September 2021 | Allow | 19 | 1 | 0 | No | No |
| 16639086 | PYRUVATE KINASE MODULATORS AND USE THEREOF | February 2020 | October 2021 | Allow | 20 | 1 | 0 | Yes | No |
| 16789707 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | February 2020 | December 2020 | Allow | 10 | 2 | 0 | No | No |
| 16638683 | 4-OXO-2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE-7-CARBOXAMIDES | February 2020 | June 2021 | Allow | 16 | 1 | 0 | No | No |
| 16638668 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | February 2020 | May 2022 | Allow | 27 | 2 | 0 | Yes | No |
| 16781748 | HETEROARYL INHIBITORS OF PDE4 | February 2020 | March 2022 | Allow | 26 | 2 | 1 | No | No |
| 16636212 | PROCESSES FOR PREPARATION OF LIFITEGRAST AND INTERMEDIATES THEREOF | February 2020 | January 2022 | Abandon | 23 | 1 | 0 | No | No |
| 16777668 | IMIDAZOLIDINEDIONE DERIVATIVES | January 2020 | June 2021 | Abandon | 17 | 2 | 0 | No | No |
| 16776091 | BIPHENYL AMIDES WITH MODIFIED ETHER GROUPS AS HSP90 INHIBITORS AND HSP70 INDUCERS | January 2020 | April 2021 | Allow | 14 | 2 | 1 | No | No |
| 16776377 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES | January 2020 | September 2020 | Allow | 8 | 1 | 0 | No | No |
| 16776374 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES | January 2020 | December 2020 | Allow | 11 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RAO, DEEPAK R.
With a 44.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 36.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner RAO, DEEPAK R works in Art Unit 1624 and has examined 2,052 patent applications in our dataset. With an allowance rate of 76.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 23 months.
Examiner RAO, DEEPAK R's allowance rate of 76.8% places them in the 45% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by RAO, DEEPAK R receive 1.48 office actions before reaching final disposition. This places the examiner in the 22% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by RAO, DEEPAK R is 23 months. This places the examiner in the 83% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a -14.7% benefit to allowance rate for applications examined by RAO, DEEPAK R. This interview benefit is in the 3% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 36.8% of applications are subsequently allowed. This success rate is in the 84% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 70.5% of cases where such amendments are filed. This entry rate is in the 92% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 85% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 89.5% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 90.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 57.4% are granted (fully or in part). This grant rate is in the 58% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 10.6% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.3% of allowed cases (in the 65% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.